Harvard Bio's Harvard Apparatus Regenerative Tech (HART) Files $20M IPO
Tweet
Share
E-mailGet Alerts HART Hot Sheet
Join SI Premium – FREE
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $20 million. Harvard Apparatus Regenerative Tech plans to list on the Nasdaq Capital Market under the ticker, "HART."
The offering is being made through Summer Street Research Partners.
Harvard Apparatus Regenerative Technology a clinical stage regenerative medicine company developing life-saving medical devices. The company is a wholly-owned subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO).
The offering is being made through Summer Street Research Partners.
Harvard Apparatus Regenerative Technology a clinical stage regenerative medicine company developing life-saving medical devices. The company is a wholly-owned subsidiary of Harvard Bioscience, Inc. (Nasdaq: HBIO).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Leader's Advantage Acquisition Corp. closes $150M IPO on Nasdaq
- Star Fashion Culture prices $9.6M public offering of Class A shares
- CrowdStrike probe closed by US prosecutors without charges
Create E-mail Alert Related Categories
IPOsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
